IMR Press / RCM / Volume 25 / Issue 2 / DOI: 10.31083/j.rcm2502061
Open Access Review
Establishment of a Comprehensive Cardiac Amyloidosis Center in a Community Hospital Setting
Show Less
1 Department of Medicine, Saint Peter’s University Hospital/Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ 08901, USA
2 Division of Cardiology, Department of Medicine, Robert Wood Johnson University Hospital, New Brunswick, NJ 08901, USA
*Correspondence: (Prabin Phuyal)
Rev. Cardiovasc. Med. 2024, 25(2), 61;
Submitted: 21 July 2023 | Revised: 28 November 2023 | Accepted: 1 December 2023 | Published: 5 February 2024
(This article belongs to the Section Cardiovascular Quality and Outcomes)
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Cardiac amyloidosis is a great masquerader that often results in misdiagnosis of this condition. Early clinical recognition is crucial for timely therapeutic interventions to improve survival in patients with cardiac amyloidosis. Currently, Food and Drug Administration (FDA)-approved medications work best if started early in the disease. Thus, to increase identification, disease awareness, expertise in diagnostic techniques, and a multidisciplinary team approach is essential. The majority of the patients (~90%) in the United States are treated in community hospitals, thus, it would be helpful for these hospitals to have their own designated, comprehensive cardiac amyloidosis center to provide care to the patients who are widespread in the community. Most of these patients are elderly, and it is difficult for these patients to travel long distances to academic amyloid centers. Our manuscript aims to provide a path to the development of cardiac amyloid centers at community hospitals.

cardiac amyloidosis
Fig. 1.
Back to top